Business
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered rademikibart designed to further confirm its unique ability to rapidly improve airway function with topline results expected in first quarter 2026 – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in mid-2026 – – Strong balance sheet with cash runway into 2027 through key clinical catalysts – SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today highlighted new mechanism of action data for rademikibart and outlined its priorities for 2026. “Following a transformative year, we are entering 2026 with a focus on clinical execution,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “The new mechanism of action (MOA) data further demonstrate rademikibart’s unique pharmacologic profile supporting its potential to rapidly reverse the negative effects on airway function of IL-4 and IL-13 resulting in rapid onset of action, greater improvement in FEV1 and reduced eosinophil-related side effects. Consistent with these MOA results, preliminary data from our ongoing Phase 1b intravenous administration (IV) study demonstrate increases in FEV1 significantly faster than observed with subcutaneous administration. We anticipate reporting topline data from this Phase 1b study in first quarter and our Seabreeze STAT studies in acute asthma and COPD midyear.” Recent Updates Development Highlights New mechanism of action data supports the use of rademikibart in combination with standard of care β-agonists to reverse acute exacerbations and for maintenance therapy in asthma and COPD. Rademikibart’s enhanced binding affinity to the IL-4R creates a more stable complex compared to dupilumab. Additionally, binding epitopes of rademikibart, but not dupilumab, on IL-4Rα overlap more closely with the conserved binding interface naturally utilized by IL-4 and IL-13 cytokines resulting in greater internalization, providing mechanistic support for rad...